<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35016">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01733420</url>
  </required_header>
  <id_info>
    <org_study_id>2011/538</org_study_id>
    <nct_id>NCT01733420</nct_id>
  </id_info>
  <brief_title>Biodentine Versus White MTA Pulpotomy</brief_title>
  <official_title>The Clinical and Radiographic Efficacy of Biodentineâ„¢ and White Mineral Trioxide Aggregate in Deciduous Molar Pulpotomy - a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to evaluate and compare three different products used for endodontic
      treatment (taking the infected nerve out of the teeth) of primary teeth.

      Null Hypothesis: The new biological products (WMTA and Biodentine) behave as good as the
      former iodoform product.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical successes after pulpotomy.</measure>
    <time_frame>at baseline visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical evaluation and radiography of the tooth is performed. Clinical criteria: abscence of post-operative pain, absence of pain on percussion and palpation, absence of abscess or swelling, absence of sinus tract or fistula and absence of pathologic tooth mobility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical success after pulpotomy.</measure>
    <time_frame>3 months after pulpotomy.</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical evaluation and radiography of the tooth is performed. Clinical criteria: abscence of post-operative pain, absence of pain on percussion and palpation, absence of abscess or swelling, absence of sinus tract or fistula and absence of pathologic tooth mobility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical successes after pulpotomy.</measure>
    <time_frame>6 months after pulpotomy.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical evaluation and radiography of the tooth is performed. Clinical criteria: abscence of post-operative pain, absence of pain on percussion and palpation, absence of abscess or swelling, absence of sinus tract or fistula and absence of pathologic tooth mobility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical successes after pulpotomy.</measure>
    <time_frame>12 months after pulpotomy.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical evaluation and radiography of the tooth is performed. Clinical criteria: abscence of post-operative pain, absence of pain on percussion and palpation, absence of abscess or swelling, absence of sinus tract or fistula and absence of pathologic tooth mobility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic successes after pulpotomy.</measure>
    <time_frame>at baseline visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiographic criteria: presence of normal periodontal ligament space, absence of internal or external root resorption, absence of canal calcification, absence of periradicular radiolucency and no loss or break of lamina dura.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic successes after pulpotomy.</measure>
    <time_frame>6 months after pulpotomy.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiographic criteria: presence of normal periodontal ligament space, absence of internal or external root resorption, absence of canal calcification, absence of periradicular radiolucency and no loss or break of lamina dura.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic successes after pulpotomy.</measure>
    <time_frame>12 months after pulpotomy.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiographic criteria: presence of normal periodontal ligament space, absence of internal or external root resorption, absence of canal calcification, absence of periradicular radiolucency and no loss or break of lamina dura.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Extensive Decay in Primary Molars</condition>
  <arm_group>
    <arm_group_label>Biodentine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulpotomy using Biodentine as pulpotomy medicine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>White Mineral trioxide Aggregate (MTA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulpotomy using white MTA as pulpotomy medicine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tempophore</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulpotomy using Tempophore as pulpotomy medicine in a control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biodentine pulpotomy</intervention_name>
    <arm_group_label>Biodentine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>White MTA pulpotomy</intervention_name>
    <arm_group_label>White Mineral trioxide Aggregate (MTA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tempophore pulpotomy</intervention_name>
    <arm_group_label>Tempophore</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (Children with carious deciduous molars indicated for pulpotomy) belonging
             to the category of ASA I according to the  'American Society of Anaesthesiologists'.

          -  Patients without any known medical history of systemic complications contradicting
             pulp treatment.

          -  Patients are indicated for treatment under general anaesthesia due to polycaries /
             fear / anxiety / very young age.

          -  Written consent is obtained from the parent/guardian after explaining the full
             details of the treatment procedure and its possible outcomes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Martens, PhD, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luc Martens, PhD, DDS</last_name>
    <email>Luc.Martens@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Martens, PhD, DDS</last_name>
      <email>Luc.Martens@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Luc Martens, PhD, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>December 18, 2012</lastchanged_date>
  <firstreceived_date>November 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
